Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer
Author Information
Author(s): Zhang Chunyu, Elkahloun Abdel G., Robertson Matthew, Gills Joell J., Tsurutani Junji, Shih Joanna H., Fukuoka Junya, Hollander M. Christine, Harris Curtis C., Travis William D., Jen Jin, Dennis Phillip A.
Primary Institution: National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Hypothesis
A sequential, combined microarray approach would be valuable to identify and validate new targets in lung cancer.
Conclusion
Loss of cytoplasmic CDK1 is associated with poor survival and chemotherapeutic resistance in lung cancer patients.
Supporting Evidence
- CDK1 loss from the cytoplasm was associated with poor prognosis in NSCLC patients.
- Loss of cytoplasmic CDK1 conferred resistance to standard chemotherapies.
- Immunohistochemical analysis showed that CDK1 was predominantly expressed in tumor tissues.
- CDK1 expression levels correlated with chemotherapeutic responsiveness in various cell lines.
Takeaway
This study found that when a protein called CDK1 is missing from the cytoplasm of lung cancer cells, it can mean the patient might not live as long and may not respond well to treatments.
Methodology
The study profiled gene expression in lung epithelial cells and validated findings through immunoblotting and tissue microarray analysis.
Potential Biases
Potential biases may arise from the selection of cell lines and the specific methodologies used for gene expression analysis.
Limitations
The study primarily focused on a specific set of genes and may not encompass all relevant biomarkers in lung cancer.
Participant Demographics
The study included 300 lung cancer cases, comprising 150 adenocarcinomas and 150 squamous cell carcinomas.
Statistical Information
P-Value
p=0.040
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website